Remizar Alpaddli, Novi Silvia Hardiany, Septelia Inawati Wanandi
{"title":"Unravelling the Association between FOXO3a and Cancer Cell Senescence: An Insight into its Role and Biological Pathway.","authors":"Remizar Alpaddli, Novi Silvia Hardiany, Septelia Inawati Wanandi","doi":"10.2174/0118746098365760250903112703","DOIUrl":"https://doi.org/10.2174/0118746098365760250903112703","url":null,"abstract":"<p><p>This review explores the intricate relationship between FOXO3a and cellular senescence in cancer, highlighting its complex and context-dependent function. FOXO3a, a transcription factor commonly known as a tumor suppressor, exhibits paradoxical roles in cancer biology. This review describes FOXO3a's dual functions in promoting tumor suppression and progression, its interplay with senescence pathways, and its impact on cancer cell phenotypes. Senescence is also known to be a tumor suppressor and a barrier against malignancies. However, persistent senescence has been found to create an adverse effect due to cancer progression and therapeutic endeavors. The review also discusses the potential of senescence management and FOXO3a modulation as novel therapeutic strategies in cancer treatment. Recent advancements in proteomics research, including FOXO3a's interactions with microRNAs, post-translational modifications, and protein-protein interactions, are also elaborated. This paper concludes by emphasizing the need to understand the role of FOXO3a in cancer biology and its potential as a biomarker and therapeutic target.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nanotechnology-Based Approaches for Combating Skin Aging: A Comprehensive Review.","authors":"Mitali, Mukesh Kumar Singh, Arun Kumar Mishra","doi":"10.2174/0118746098384581250904035955","DOIUrl":"10.2174/0118746098384581250904035955","url":null,"abstract":"<p><strong>Introduction: </strong>The aging of skin is a multifaceted biological phenomenon influenced by both intrinsic and extrinsic factors. As awareness among the public increases, there is a growing interest in natural ingredients and cutting-edge cosmetic solutions that enhance skin appearance and mitigate the aging process. Nanotechnology has emerged as a significant field within cosmeceuticals, providing innovative solutions that overcome the limitations of conventional cosmetic formulations by enhancing delivery, stability, and targeted efficacy.</p><p><strong>Methods: </strong>This review synthesized contemporary research on nanotechnology-driven approaches utilized in anti-aging skincare. A comprehensive search of scientific databases, including Pub- Med, Scopus, and Google Scholar, was performed to identify research articles and review papers using keywords, such as \"nanotechnology,\" \"skin aging,\" \"anti-aging cosmetics,\" \"nanocarriers,\" and \"bioactive compounds.\" The emphasis was placed on studies that highlight nanosized delivery systems and their mechanisms in addressing issues related to skin aging.</p><p><strong>Results: </strong>Bioactive compounds targeting anti-aging, such as antioxidants (including ascorbic acid, alpha-tocopherol, lipoic acid, and coenzyme Q10) and plant extracts (such as green tea, turmeric, and resveratrol), were successfully integrated into nanocarrier systems. These systems, comprising lipid nanoparticles, polymeric carriers, nanoemulsions, dendrimers, and fullerenes, demonstrate improved penetration, stability, and controlled release compared to traditional formulations, thereby enhancing the effectiveness of active ingredients in addressing signs of aging.</p><p><strong>Discussion: </strong>Nanotechnology-driven skincare has demonstrated enhanced delivery, stability, and bioavailability of anti-aging compounds, addressing limitations of conventional formulations. Nanosized carriers improve penetration and controlled release, optimizing the functional benefits of antioxidants and botanical extracts. However, concerns related to safety, toxicity, and regulatory compliance require further investigation. Sustainable nanocarrier development and interdisciplinary collaborations will be essential for balancing efficacy with safety. Continued research will be crucial to establishing standardized guidelines and ensuring the successful commercialization of nano-based anti-aging cosmetics.</p><p><strong>Conclusion: </strong>Nanotechnology presents significant potential for the development of effective antiaging cosmetic products. The use of nanosized delivery systems significantly enhances the efficacy of active ingredients, providing a viable alternative to traditional formulations. Nonetheless, challenges related to safety, toxicity, regulatory compliance, and long-term clinical application must be addressed in future research to facilitate the successful commercialization of these products. Additionally, future ","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145112125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hybrid Cosmeceutical Innovations for Aging Skin: Bridging Functional Skincare and Therapeutic Benefits through Multifunctional Formulations.","authors":"Shikha Baghel Chauhan, Indu Singh, Manisha Singh, Mohit Singh","doi":"10.2174/0118746098369285250902044905","DOIUrl":"https://doi.org/10.2174/0118746098369285250902044905","url":null,"abstract":"<p><p>A new generation of hybrid cosmetics has come into existence, providing an efficient means to achieve both skincare and aesthetic objectives with only one product. These cosmetics incorporate ingredients from natural and synthetic sources, making use of cutting-edge technologies to improve efficacy, sustainability, and customer pleasure. This review paper will focus on the effects of hybrid cosmetics on different types of skin cells, the technologies employed, and the role of ingredients like botanical extracts, marine-based active ingredients, and synthetic compounds in the cosmetic formulations, in order to provide improved skincare benefits. Various technologies like nanotechnology, encapsulation technique, transdermal patches, electroporation, and iontophoresis are analyzed for their role in enhancing efficacy and sustainability. Hybrid cosmetics containing natural ingredients of marine origin, like Laminaria japonica and Pseudopterogorgia elisabethae, as well as botanical extracts like Resveratrol, provide safe, ecofriendly, and sustainable cosmetics, whereas synthetically derived compounds that are used in the cosmetic industry, like Hyaluronic acid and Niacinamide, provide quick action and targeted delivery. The findings of this review suggest novel dual approaches for developing a range of hybrid products to meet the increasing needs of consumers, as well as techniques for improving stability and efficacy. Using natural ingredients aligns with the growing trend toward sustainability in cosmetics. Synthetic ingredients have been developed for precise delivery, rapid action, and affordability. However, by implementing appropriate strategies for technology and ingredient selection, consumers' demands for effective products can be met.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vasanth S, Rakhi Mishra, Subhashree Sahoo, Sadia Parveen, Zuber Khan, Mumtaz, Ruqaiya, Rahul Pal
{"title":"Advancing Mitochondrial Health in Huntington Disease (HD): Small Molecule Therapies and Neurodegeneration.","authors":"Vasanth S, Rakhi Mishra, Subhashree Sahoo, Sadia Parveen, Zuber Khan, Mumtaz, Ruqaiya, Rahul Pal","doi":"10.2174/0118746098387655250818072130","DOIUrl":"https://doi.org/10.2174/0118746098387655250818072130","url":null,"abstract":"<p><p>Huntington's disease (HD) is a severe neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin gene, leading to the production of a mutant huntingtin protein. This mutation results in progressive motor, cognitive, and psychiatric impairments, alongside significant neuronal loss. Mitochondrial dysfunction plays a pivotal role in the pathophysiology of HD, contributing to disease progression and neuronal death. This article aims to evaluate small molecule-based therapeutic strategies designed to enhance mitochondrial function as a potential approach to alleviate symptoms and slow the progression of HD and related neurodegenerative disorders. A comprehensive review of recent literature is conducted to identify small molecules targeting mitochondrial dysfunction from Google Scholar, Pub- Med/Medline/PMC, ScienceDirect, Elsevier, Google Patents, and Clinicaltrials.gov.in, among others. The analysis focuses on their mechanisms of action, including reducing oxidative stress, enhancing mitochondrial biogenesis, and improving mitochondrial dynamics and function. The review identifies several promising small molecules capable of targeting mitochondrial dysfunction. These agents demonstrate potential in preclinical studies to alleviate HD symptoms and modify disease progression by addressing key aspects of mitochondrial health. Small molecule therapies targeting mitochondrial dysfunction offer considerable promise for treating HD. However, further research is required to optimize these therapies for clinical use and to evaluate their long-term impact on disease progression to fully establish their therapeutic efficacy.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Revolutionizing Neurodegenerative Disease Management: The Synergy of AI and Pharmacy.","authors":"Krishnaveni Manubolu, Raveesha Peeriga","doi":"10.2174/0118746098375978250820220024","DOIUrl":"https://doi.org/10.2174/0118746098375978250820220024","url":null,"abstract":"<p><p>Neurodegenerative diseases, including Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS), represent major healthcare challenges worldwide. Despite advances in diagnosis and treatment, these conditions remain incurable, and there is a need for more effective management strategies. The integration of artificial intelligence (AI) in healthcare has emerged as a promising solution, offering new approaches to diagnosis, personalized treatment, and patient care. This paper explores the potential of AI to revolutionize the management of neurodegenerative diseases, with a focus on its synergistic role in pharmacy. By leveraging AI in drug discovery, personalized treatment plans, and clinical decision-making, AI can enhance therapeutic outcomes and improve patient quality of life. The study reviews the current landscape of AI applications in neurodegenerative disease management, with a focus on pharmacy-related interventions. The review includes AI-driven approaches in genomics, biomarkers, drug repurposing, and clinical trials. It also examines AI's role in optimizing pharmaceutical care, improving medication adherence, and tailoring treatments based on individual genetic profiles. AI has demonstrated its capability to analyze vast datasets, from genetic information to clinical records, to identify novel drug targets and predict patient responses to specific therapies. The use of AI in precision medicine has enabled more accurate diagnosis and has facilitated the development of personalized treatments for neurodegenerative diseases. Additionally, AI tools are enhancing medication management by providing personalized therapy adjustments and improving adherence. AI offers transformative potential for the future of neurodegenerative disease management. Its integration into pharmacy practice promises more effective, individualized treatments, accelerating drug discovery, and optimizing patient care. As AI technologies continue to advance, their role in managing complex neurological disorders will become increasingly vital.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Final Diagnoses of Elderly Emergency Patients Presenting with Weakness and Fatigue in Southeastern Iran.","authors":"Shima Groohi-Sardou, Alireza Dehghani Bahador, Rasoul Raesi, Kiavash Hushmandi, Salman Daneshi","doi":"10.2174/0118746098373552250824195800","DOIUrl":"https://doi.org/10.2174/0118746098373552250824195800","url":null,"abstract":"<p><strong>Introduction: </strong>Weakness and fatigue in the elderly present major health challenges, highlighting the need for prompt diagnosis and accurate identification of their causes in emergency departments. This study aimed to investigate the final diagnoses of elderly patients presenting with symptoms of weakness and fatigue in the emergency department.</p><p><strong>Methods: </strong>This cross-sectional study surveyed 200 elderly individuals (aged ≥60) with complaints of weakness and fatigue at Imam Khomeini Hospital in Jiroft, Kerman, Iran, in 2023. The collected data were extracted from patients' medical records using a checklist, and data analysis was performed using SPSS 22 software, employing both descriptive and inferential statistical methods at a significance level of p < 0.05.</p><p><strong>Results: </strong>The mean age of the patients was 78.2 years, with 56% of the patients being female. During hospitalization, 7.5% of the patients died, with 53.33% of these being men. Underlying heart diseases were present in 13.5% of the patients, with 55.6% of those being women. High blood pressure was prevalent in 81% of the patients.</p><p><strong>Discussion: </strong>Infectious diseases were the most common final diagnosis, accounting for 27% of cases, followed by cardiovascular diseases at 18.5%. Among patients with infectious diseases, 85.5% had high blood pressure.</p><p><strong>Conclusion: </strong>The results indicate that weakness and fatigue in elderly patients may signal serious underlying conditions. Additionally, the strong link between high blood pressure and infectious diseases underscores the importance of closely monitoring the overall health of these patients.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dendrimers: Advancing Therapeutic Strategies for Dementia.","authors":"Aditya Singh, Shubhrat Maheshwari, Vaseem Ahamad Ansari, Amita Verma, Tarique Mahmood Ansari, Juber Akhtar, Farogh Ahsan, Vishal Kumar Vishwakarma, Rufaida Wasim","doi":"10.2174/0118746098343913250818112618","DOIUrl":"https://doi.org/10.2174/0118746098343913250818112618","url":null,"abstract":"<p><p>Dementia, characterized by a progressive decline in cognitive function, poses a significant challenge to global healthcare systems, with current therapeutic approaches offering limited efficacy. The development of nanotechnology-based drug delivery systems has introduced promising avenues for enhancing the treatment of neurodegenerative disorders such as Alzheimer's disease. Dendrimers, with their highly branched, nanoscale structure, provide an innovative platform for targeted drug delivery to the brain. Dendrimers serve as nanoscale drug carriers that facilitate controlled drug release, enhance bioavailability, and improve penetration across the blood-brain barrier (BBB), leading to superior therapeutic efficacy in neurodegenerative disorders. In particular, dendrimers can encapsulate both hydrophilic and hydrophobic drugs, increasing their stability and minimizing systemic side effects. This review explores the unique properties of dendrimers, focusing on their potential as drug delivery vehicles in dementia treatment. We also highlight advancements in the design and application of dendrimer-based therapeutics, emphasizing their role in targeting key pathological mechanisms underlying dementia. Through these approaches, dendrimers represent a promising strategy for developing more effective and personalized treatment modalities for patients suffering from cognitive impairment and dementia.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Advances in Nanotechnology for Targeted Drug Delivery in Alzheimer's Disease.","authors":"Shubhrat Maheshwari, Pavan Kumar, Vaibhav Dwivedi, Ankita Mishra, Vipul Kumar Singh, Aditya Singh","doi":"10.2174/0118746098359258250727103551","DOIUrl":"https://doi.org/10.2174/0118746098359258250727103551","url":null,"abstract":"<p><p>Alzheimer's Disease (AD) is a complex neurodegenerative disorder characterized by progressive cognitive decline and hallmark pathological features, such as amyloid-beta plaques and tau protein tangles. Despite substantial research, current therapeutic strategies remain primarily symptomatic, with limited success in preventing or reversing disease progression. One major challenge is the Blood-Brain Barrier (BBB), which restricts the delivery of therapeutic agents to the brain. Nanotechnology provides innovative solutions to these challenges by enabling the development of targeted drug delivery systems tailored to AD's unique pathophysiology. Nanoparticles offer several advantages for AD therapy, including their small size, surface modifiability, and the ability to traverse the BBB. These carriers can enhance drug stability, prolong systemic circulation, and enable controlled drug release, reducing systemic toxicity while maximizing therapeutic efficacy. Among various approaches, nanoparticles functionalized with ligands targeting AD show promise in promoting the clearance of pathological aggregates, potentially slowing disease progression and alleviating neurotoxicity. Liposomes, polymeric nanoparticles, dendrimers, and exosomes are notable nanocarriers that have been successfully engineered to deliver a range of therapeutic agents, including anti-amyloid drugs, neuroprotective compounds, and gene therapies. Recent advancements also emphasize stimulus-responsive nanocarriers that release drugs in response to specific pathological cues, further enhancing treatment precision. This article delves into the most recent advancements in nanotechnology for AD therapy, and the potential of these innovative systems to overcome long-standing barriers in AD treatment and paving the way for more effective and targeted interventions.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Han Li, Qiong Han, Yan Liu, Jiaxin Duan, Beiping Su, Zhenlin Tang, Xinhe Huang
{"title":"Synergistic Enhancement of Anti-aging Effects on Human Umbilical Vein Endothelial Cells Treated With the Combination of Ferulic Acid and Rapamycin.","authors":"Han Li, Qiong Han, Yan Liu, Jiaxin Duan, Beiping Su, Zhenlin Tang, Xinhe Huang","doi":"10.2174/0118746098383170250728163902","DOIUrl":"https://doi.org/10.2174/0118746098383170250728163902","url":null,"abstract":"<p><strong>Introduction: </strong>Aging is a complex process involving cellular, genetic, metabolic, and mitochondrial changes. While significant progress has been made in understanding aging mechanisms and developing anti-aging drugs, single-drug treatments have limitations. This paper aims to investigate the synergistic effects of Ferulic acid (FA) and Rapamycin (Rapa) on anti-aging and to elucidate their underlying mechanisms, providing novel strategies for future anti-aging therapies.</p><p><strong>Methods: </strong>The safe concentration ranges of FA and Rapa for Human umbilical vein endothelial cells (HUVECs) were determined via Cell counting kit (CCK-8) and Senescence-associated β- Gal staining, with EC50 calculated by GraphPad Prism 8.0.2. Effects on cell cycle arrest and ROS in D-gal-induced aging HUVECs were assessed, with synergistic mechanisms explored by Western Blot and RT-qPCR for aging markers, inflammatory factors, and fibrosis genes.</p><p><strong>Results: </strong>CCK-8 showed that 20-160 μM FA and 50-200 pM Rapa enhanced HUVECs proliferation, with EC50 of 37.78 μM for FA and 48.32 pM for Rapa. The optimal 1:2 combination ratio demonstrated reduced G0/G1 cells, decreased ROS, and lowered NF-κB p65, p53, IL-1β, and TNF-α expression. It also inhibited fibrosis-related gene transcription, downregulating aging markers and maintaining cellular homeostasis.</p><p><strong>Discussion: </strong>These results align with previous studies highlighting FA's antioxidant properties and Rapa's role in mTOR inhibition, suggesting that their combination targets multiple aging pathways simultaneously. The dual approach-reducing oxidative damage while modulating inflammation and fibrosis-may offer superior efficacy compared to single-drug interventions.</p><p><strong>Conclusion: </strong>In summary, this dual-target strategy presents a promising avenue for developing advanced anti-aging therapies, warranting further investigation in preclinical and clinical settings.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Deciphering the Potential of Bone Morphogenetic Pathway (BMP) in the Pathogenesis Of Depression.","authors":"Uma, Ravinder Verma, Pooja Mathur, Anju, Nisha Tiwetia, Ritu","doi":"10.2174/0118746098352786250730100521","DOIUrl":"https://doi.org/10.2174/0118746098352786250730100521","url":null,"abstract":"<p><p>Depression is a prevalent mental health disorder, profoundly impacting individuals and often exacerbated by stressful experiences. Current treatment options have limitations, including reduced efficacy and undesirable side effects. While antidepressant medications target distinct brain regions, their precise mechanisms influencing behavior remain incompletely elucidated. Recent research underscores the significance of the bone morphogenetic protein (BMP) signaling pathway within the hippocampus in mediating the effects of various antidepressants. Notably, these drugs inhibit BMP signaling, thereby augmenting neurogenesis in the hippocampus. Inhibiting BMP signaling specifically in newly generated brain cells elicits antidepressant effects, whereas suppressing these cells impedes such outcomes. This underscores the pivotal role of BMP signaling in the mechanism of antidepressant action. Adult neurogenesis, particularly in the hippocampus, emerges as pivotal for emotional regulation and stress response. Stress reduces the generation of new brain cells, whereas prolonged use of antidepressants promotes neurogenesis, suggesting a link between neurogenesis and depression. Investigating the molecular and cellular mechanisms underlying depression, anxiety, and antidepressant efficacy holds promise for the development of improved treatments characterized by rapid relief and reduced side effects.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}